Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Clearside Biomedical, Inc. (CLSDQ) had Return on Tangible Equity of 11.07% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.20M |
|
$-5.97M |
|
-- |
|
$0.20M |
|
$7.24M |
|
$-7.04M |
|
$1.07M |
|
$-5.97M |
|
$-5.97M |
|
$-5.97M |
|
$-5.97M |
|
$-5.97M |
|
$-5.97M |
|
$-7.04M |
|
$-6.96M |
|
5.23M |
|
5.23M |
|
$-1.14 |
|
$-1.14 |
|
| Balance Sheet Financials | |
$8.25M |
|
$2.98M |
|
$3.39M |
|
$11.64M |
|
$2.77M |
|
-- |
|
$62.82M |
|
$65.59M |
|
$-53.95M |
|
$-53.95M |
|
$-53.95M |
|
5.23M |
|
| Cash Flow Statement Financials | |
$-16.04M |
|
$-0.01M |
|
$2.83M |
|
$20.02M |
|
$6.80M |
|
$-13.22M |
|
$2.16M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-3502.49% |
|
-3502.49% |
|
-- |
|
-2971.14% |
|
-2971.14% |
|
$-16.05M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
0.76 |
|
119.10 |
|
11.07% |
|
|
Return on Tangible Equity |
11.07% |
-51.30% |
|
11.07% |
|
$-10.31 |
|
$-3.07 |
|
$-3.06 |
|